Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting for its KRAS G12C inhibitor glecirasib (JAB-21822) in combination with an SHP2 inhibitor (JAB-3312) as a frontline treatment for non-small cell lung cancer (NSCLC) patients with the KRAS G12C mutation.
Glecirasib, developed by Jacobio, has received orphan drug designation in the US and breakthrough therapy designation in China for its potential in treating pancreatic cancer. The SHP2 inhibitor JAB-3312 is a highly selective allosteric inhibitor with the potential to be best-in-class and is currently undergoing multiple clinical studies in China, the US, and Europe.
As of April 7, 2024, 194 patients participated in the Phase II trial combining glecirasib with JAB-3312 (NCT05288205), including 102 frontline NSCLC patients with a median follow-up time of 10.1 months. The confirmed objective response rate (cORR) was 64.7% (66/102), the disease control rate (DCR) was 93.1% (95/102), and the median progression-free survival (mPFS) was 12.2 months. The trial explored a total of 7 different dose cohorts, identifying the optimal dose group as glecirasib at 800mg daily combined with JAB-3312 at 2mg daily on a one week on, one week off schedule. The cORR for the optimal dose group was 77.4% (18/31), with 54.8% (17/31) of patients achieving a deep response of tumor shrinkage by more than 50%. The mPFS for the optimal dose group was not yet mature. The safety profile in the frontline NSCLC cohort was consistent with the overall study population, indicating manageable overall safety.- Flcube.com
